The third quarter in figures
- Net sales were TSEK 7,248 (4,941), +47%.
- The loss after tax was TSEK 12,786 (8,765).
-
The loss per share was
SEK 0.11 (0.13). - The cash flow from current operations was negative in the amount of TSEK 17,827 (9,718).
- The gross margin was 68.2% (58.4%).
- Electrode sales volume increased by 60% and was 16,922 (10,592) units. Repeat sales of electrodes to existing customers increased by 66%.
January - September in figures
- Net sales were TSEK 17,481 (12,927), +35%.
- The loss after tax was TSEK 35,044 (27,713).
-
The loss per share was
SEK 0.34 (0.40). - The cash flow from current operations was negative in the amount of TSEK 34,633 (29,783).
- The gross margin was 67.5% (63.3%).
- Electrode sales volume increased by 32% and was 39,866 (30,172) units. Repeat sales of electrodes to existing customers increased by 33%.
Important events during the quarter
- Overall sales increased by 47% (+33, before currency effects). Sales in
Germany increased by 65% (49% in local currency). Sales in the US skin cancer market was 31% lower than Q3 2022. Sales within the skin barrier segment increased by 42%. SciBase appointedPia Renaudin as new Chief Executive Officer.
SciBase signed new collaboration agreement withBare Dermatology to advance skin cancer detection inTexas .
SciBase strengthens US team with experienced Dermatology executive.
- A study was published in the journal Allergy showing that Nevisense detects skin barrier dysfunction in children with Atopic Dermatitis. The study was performed together with the University Children's Hospital Zürich.
-
The results from a collaborative scientific project with the
Swiss Institute of Allergy and Asthma Research (SIAF) inDavos, Switzerland was published in the journal Allergy. The study is the first to use Nevisense to measure skin barrier function in human excised skin samples, demonstrating Nevisense as an effective laboratory research device.
Important events after the end of the period
- A nominating committee for the Annual General Meeting in 2024 was appointed.
Financial overview
THE GROUP | 2023 | 2022 | 2023 | 2022 | Rolling-12 | 2022 |
Net sales, SEK ths | 7 248 | 4 941 | 17 481 | 12 927 | 22 444 | 17 890 |
Gross margin, % | 68,2% | 58,4% | 67,5% | 63,3% | 66,1% | 62,8% |
Equity/Asset ratio, % | 72,4% | 72,5% | 72,4% | 72,5% | 72,4% | 50,6% |
Net indebtness, multiple | 0,38 | 0,38 | 0,38 | 0,38 | 0,38 | 0,98 |
Cash equivalents, SEK ths | 52 353 | 34 014 | 52 353 | 34 014 | 52 353 | 18 832 |
Cashflow from operating activities, SEK ths | -17 827 | -9 718 | -34 633 | -29 873 | -49 225 | -44 466 |
Earnings per share (before and after dilution), SEK | -0,11 | -0,13 | -0,34 | -0,40 | -0,53 | -0,63 |
Shareholder's equity per share, SEK | 0,50 | 0,57 | 0,58 | 0,57 | 0,52 | 0,37 |
Average number of shares, 000' | 119 831 | 68 475 | 104 029 | 68 475 | 95 141 | 68 475 |
Number of shares at closing of period, 000'* | 119 831 | 68 475 | 119 831 | 68 475 | 119 831 | 68 475 |
Share price at end of period, SEK | 1,24 | 3,70 | 1,24 | 3,70 | 1,24 | 3,82 |
Number of sold electrodes, pieces | 16 922 | 10 592 | 39 866 | 30 172 | 51 406 | 41 712 |
Average number of employees | 23 | 20 | 22 | 19 | 21 | 20 |
This information is information that
This report has been comprehensively reviewed by the Company's auditors.
Contact person:
Michael Colérus, CFO, +46 70 341 34 72
For more information, please contact:
Tel: +46 73 206 98 02
Email: pia.renaudin@scibase.com
Certified Advisor (CA):
Tel: +46 8 580 065 99
Email: ca@vatorsec.se
About
https://news.cision.com/scibase/r/interim-report,c3873021
https://mb.cision.com/Main/12371/3873021/2420869.pdf
(c) 2023 Cision. All rights reserved., source